Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression

<p>Figure S.6</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Xufeng Lu (14960724) (author)
Kolejni autorzy:	Dazhuan E. Xin (14960727) (author), Juanjuan K. Du (14960730) (author), Quanli C. Zou (14960733) (author), Qian Wu (14960736) (author), Yanan S. Zhang (14960739) (author), Wenhai Deng (14960742) (author), Jicheng Yue (14960745) (author), Xing S. Fan (14960748) (author), Yuanyuan Zeng (9330065) (author), Xiaju Cheng (14960751) (author), Xue Li (14960754) (author), Zhaoyuan Hou (14960757) (author), Man Mohan (14960760) (author), Ting C. Zhao (14960763) (author), Xiaomei Lu (14960766) (author), Zhijie Chang (14960769) (author), Liyan Xu (14960772) (author), Yu Sun (14960775) (author), Xiongbing Zu (14960778) (author), Yu Zhang (14960781) (author), Y. Eugene Chinn (14960784) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Cancer Biology Immuno-oncology Gynecological Cancers Uterine cancer Immunotherapy Combination immunotherapy Oncogenes & Tumor Suppressors Tumor suppressor genes
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
od: Daniel S. Green (15047598)
Wydane: (2025)

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
od: Francisco Exposito (16721403)
Wydane: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
od: Francisco Exposito (16721403)
Wydane: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
od: Francisco Exposito (16721403)
Wydane: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
od: Francisco Exposito (16721403)
Wydane: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
od: Francisco Exposito (16721403)
Wydane: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
od: Renumathy Dhanasekaran (14962092)
Wydane: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
od: Yemin Wang (17315078)
Wydane: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
od: Isha Mondal (16721699)
Wydane: (2025)

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Wydane: (2025)

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Wydane: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Wydane: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Wydane: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Wydane: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Wydane: (2025)

Supplementary Table S1-19 from Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations
od: Yuxi Liu (15293121)
Wydane: (2025)

Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
od: Cheng-Kai Wang (14963880)
Wydane: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
od: Kankan Cao (16437263)
Wydane: (2025)

Data Sheet 1_Intra-voxel incoherent motion biomarker repeatability in healthy volunteers and sensitivity to chemoradiotherapy-induced changes in patients with uterine cervical cancer.pdf
od: Damien J. McHugh (22686269)
Wydane: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
od: Andrew Nguyen (17142197)
Wydane: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
od: Amir T. Fathi (15313195)
Wydane: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
od: Amir T. Fathi (15313195)
Wydane: (2025)

Supplementary Table 1 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer
od: Qin-Shu Li (16990832)
Wydane: (2025)

Supplementary Table 2 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer
od: Qin-Shu Li (16990832)
Wydane: (2025)

Supplementary Table 1 from Monounsaturated and Diunsaturated Fatty Acids Sensitize Cervical Cancer to Radiation Therapy
od: Naoshad Muhammad (14960127)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_schrtn2vj4c2u0be66rf1vk23s